{"public_id":"co_2b1cbac5fc78275535a7bd59e4ee198b","status":"active","merged_into_public_id":null,"resolved_public_id":"co_2b1cbac5fc78275535a7bd59e4ee198b","name":"interferon-gamma","description":"A cytokine released by sensitized T cells upon antigen stimulation, measured here as the primary IGRA readout to quantify T-cell immune responses to SARS-CoV-2 vaccination.","aliases":["IFNγ","IFN-gamma"],"types":["cytokine","biomarker"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":252457006,"title":"An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results","citation_count":2,"url":"https://sah.borca.ai/papers/252457006"}],"claims":[{"public_id":"cl_978f041afe5013ab913756dfeff96caa","text":"IFNγ concentrations were higher in COVID-19 convalescents than in naïve participants at both timepoints—before and 21 days after the BNT162b2 booster.","corpus_id":252457006,"url":"https://sah.borca.ai/claims/cl_978f041afe5013ab913756dfeff96caa"},{"public_id":"cl_d000129c721da44773f8ccc1ac734a0c","text":"IGRA test results showed a significant increase at 21 days after the BNT162b2 booster compared to pre-booster values in ChAd-primed participants.","corpus_id":252457006,"url":"https://sah.borca.ai/claims/cl_d000129c721da44773f8ccc1ac734a0c"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_2b1cbac5fc78275535a7bd59e4ee198b","url":"https://sah.borca.ai/concepts/co_2b1cbac5fc78275535a7bd59e4ee198b"}